GlassScriptPhysician profile
Faraz Khursheed
NPI 1376705681
$11,863.25
in general payments reported to CMS, 2019-2025
38 companies · $4,270 in 2025
The $4,270 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $2,012 · 2021: $2,024 · 2022: $1,147 · 2023: $300 · 2024: $321 · 2025: $4,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,891.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,447.60 | 2019-2024 | Eterna |
| Biotronik Nro, INC. | $3,988.13 | 2025 | Prospera |
| Collegium Pharmaceutical, INC. | $551.71 | 2019-2021 | |
| Zyla Life Sciences, INC. | $439.32 | 2019-2020 | |
| Pfizer INC. | $400.81 | 2019-2025 | |
| Abbvie INC. | $383.80 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $371.88 | 2019-2025 | |
| Allergan, INC. | $151.43 | 2019-2020 | |
| Redhill Biopharma INC. | $135.19 | 2021-2022 | |
| Boston Scientific Corporation | $133.59 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Biodelivery Sciences International, INC. | $96.41 | 2019-2021 | |
| Medtronic USA, INC. | $89.30 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.22 | 2019-2022 | |
| Nevro Corp. | $50.18 | 2019-2024 | Senza |
| Astrazeneca Pharmaceuticals LP | $44.45 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $40.17 | 2025 | Senza |
| Medtronic, INC. | $39.95 | 2021-2022 | |
| Daiichi Sankyo INC. | $38.99 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.94 | 2022 | |
| Nalu Medical, INC. | $26.19 | 2025 | Nalu Neurostimulation System |
| Hyperfine Operations, INC. | $25.53 | 2025 | Swoop |
| Horizon Therapeutics Plc | $25.00 | 2019 | |
| Grt US Holding, INC. | $23.37 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $22.99 | 2023 | Austedo |
| Assertio Therapeutics, INC. | $22.05 | 2020 | |
| Masimo Corporation | $21.56 | 2023 | Patient Safetynet System |
| Djo, LLC | $21.29 | 2024 | Chattanooga |
| Tersera Therapeutics LLC | $21.18 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $19.84 | 2019 | |
| Shionogi INC | $18.97 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.88 | 2021 | |
| Orexo US, INC. | $15.53 | 2022 | |
| Forte Bio-Pharma LLC | $15.07 | 2023 | Prolate, Nalocet |
| Kaleo, INC. | $14.30 | 2019 | |
| Sentynl Therapeutics, INC. | $12.99 | 2019 | |
| Vertiflex, INC. | $12.30 | 2019 | |
| Hikma Pharmaceuticals USA | $12.14 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faraz Khursheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.